Ozempic while breastfeeding — limited human data, label recommendation, and what the guidance is for nursing mothers on semaglutide.
Short answer: Data on semaglutide in breastfeeding is limited — it was present in animal milk; human transfer is unknown. The label weighs benefits vs potential infant risk; the practical position is to discuss with your doctor — many clinicians defer GLP-1s until after breastfeeding.
What the label says
Semaglutide was present in rat milk; human data is lacking. The FDA label asks prescribers to weigh the drug's benefit to the mother against potential infant risk — no blanket prohibition, but no clean safety data either.
Practical approach
Because human evidence is absent, most clinicians defer weight-management GLP-1s until breastfeeding ends. Diabetes control during lactation typically uses insulin (established infant-safe profile). Discuss your specific situation.
No human data — most clinicians recommend deferring until after breastfeeding, or using established alternatives like insulin if diabetes treatment is needed.
FDA label — lactation section; LactMed guidance.